Lanean...
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
The KRAS gene is frequently mutated in multiple cancer types, but it fell off the drug discovery radar for many years because of its inherent “undruggable” structure and undefined biological properties. As reported in the paper entitled “Suppression of KRas-mutant cancer through the combined inhibit...
Gorde:
| Argitaratua izan da: | Chin J Cancer |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5086049/ https://ncbi.nlm.nih.gov/pubmed/27793187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40880-016-0154-7 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|